[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A, GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network: A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer; 2008 Oct 1;113(7):1588-95
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
  • BACKGROUND: Bisphosphonates (BPs) are effective in the prevention and treatment of skeletal-related events (SREs) in patients with symptomatic myeloma who are receiving chemotherapy.
  • Few studies published to date have explored the role of BPs in patients with untreated, asymptomatic myeloma (AM).
  • RESULTS: After a median follow-up of 64.7 person-months, 44.4% of patients in the zoledronic acid group and 45.1% of the control group progressed to 'symptomatic' myeloma requiring chemotherapy (P = .9307).
  • The median time to progression was 67 months and 59 months for the treatment and control groups, respectively (P = .8312).
  • More frequent adverse events observed in the zoledronic acid-treated group were asymptomatic hypocalcemia and fever.
  • One patient developed reversible osteonecrosis of the jaw.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Diseases / prevention & control. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Multiple Myeloma / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer. 2008 Nov 15;113(10):2835
  • (PMID = 18683218.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


2. Koski AM, Sikiö A, Forslund T: Teriparatide treatment complicated by malignant myeloma. BMJ Case Rep; 2010;2010
Hazardous Substances Data Bank. TERIPARATIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teriparatide treatment complicated by malignant myeloma.
  • Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide (Forsteo in Europe), is a new compound that has been introduced and shown to be successful in the treatment of osteoporosis.
  • In malignant myeloma there is an imbalance between osteoclast and osteoblast activity with involvement of the RANKL/OPG system among others.
  • We report a case with monoclonal gammopathy of uncertain significance (MGUS) who developed malignant myeloma after teriparatide treatment and we suggest that in addition to malignant myeloma and smouldering myeloma, MGUS should also be considered contraindicated for teriparatide treatment.
  • [MeSH-major] Fractures, Spontaneous / etiology. Fractures, Spontaneous / radiography. Multiple Myeloma / chemically induced. Osteoporosis, Postmenopausal / drug therapy. Teriparatide / adverse effects
  • [MeSH-minor] Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Fracture Fixation, Internal / methods. Humans. Middle Aged. Monitoring, Physiologic / methods. Risk Assessment

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3332-6 [15240611.001]
  • [Cites] Br Med J. 1980 Jun 7;280(6228):1340-4 [6992932.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Jul-Sep;63(7-8):502-3 [8896065.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):688-703 [15769903.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2765-70 [17192542.001]
  • [Cites] N Engl J Med. 2001 May 10;344(19):1434-41 [11346808.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):916-25 [11159865.001]
  • [Cites] Toxicol Pathol. 2002 May-Jun;30(3):312-21 [12051548.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1655-65 [9626070.001]
  • (PMID = 22767690.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 10T9CSU89I / Teriparatide
  • [Other-IDs] NLM/ PMC3027506
  •  go-up   go-down


3. Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB: Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood; 2008 Oct 15;112(8):3122-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
  • Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy.
  • In the first 2 years, THAL dose reduction was required in 86% and drug was discontinued in 50%.
  • Within 4 years, 63% improved, including 25% qualifying for partial response (PR); by then, 34 patients had progressed and 17 required salvage therapy.
  • Unexpectedly, attaining PR status was associated with a shorter time to salvage therapy for disease progression (P < .001), perhaps reflecting greater drug sensitivity of more aggressive disease.
  • Four-year survival and event-free survival estimates of 91% and 60%, respectively, together with a median postsalvage therapy survival of more than 5 years justify the conduct of a prospective randomized clinical trial to determine the clinical value of preemptive therapy in SMM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Diphosphonates / administration & dosage. Immunosuppressive Agents / administration & dosage. Multiple Myeloma / drug therapy. Multiple Myeloma / prevention & control. Precancerous Conditions / drug therapy. Thalidomide / administration & dosage
  • [MeSH-minor] Disease Progression. Disease-Free Survival. Humans. Multivariate Analysis. Salvage Therapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] Am J Hematol. 1995 Sep;50(1):9-14 [7545353.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):593-602 [9469347.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1885-92 [9607928.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):530-2 [9827929.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1692-700 [17023574.001]
  • [Cites] N Engl J Med. 2007 Jun 21;356(25):2582-90 [17582068.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1274-6 [11480571.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Blood. 2008 Jan 15;111(2):785-9 [17942755.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):536-42 [11740806.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] N Engl J Med. 1980 Jun 12;302(24):1347-9 [7374679.001]
  • [Cites] Am J Med. 1993 Jan;94(1):57-61 [8420300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):810-4 [9217181.001]
  • (PMID = 18669874.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00083382
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055819; United States / NCI NIH HHS / CA / CA55819
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; OYY3447OMC / pamidronate
  • [Other-IDs] NLM/ PMC2569167
  •  go-up   go-down


Advertisement
4. Danilatou V, Liapi D, Psyllaki M, Chatzivasili A, Chronaki I, Heliakis P: Neurofibromatosis type I and smoldering multiple myeloma: a case report. Hematology; 2006 Feb;11(1):45-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type I and smoldering multiple myeloma: a case report.
  • We present a case of a 64-year-old woman with neurofibromatosis (NF1) and smoldering multiple myeloma (SMM).
  • SMM was diagnosed 9 years ago when the asymptomatic patient was found to have mild anemia, IgA paraproteinemia, hypogammaglobulinemia, osteopenia without any lytic bone lesions and bone marrow plasmacytosis.
  • During follow-up period she remained stable in an excellent clinical condition without requiring any therapy for almost 4 years.
  • Forty-two months after diagnosis she had a femoral fracture and since then biphosphonates have been administered intravenously, once monthly.
  • We will discuss the probable pathogenesis of plasma cell dyscrasia in NF1 patients, as well as the likely antimyeloma activity of biphoshonates.
  • [MeSH-major] Bone Density Conservation Agents / administration & dosage. Diphosphonates / administration & dosage. Multiple Myeloma / drug therapy. Multiple Myeloma / etiology. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / drug therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16522549.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Immunoglobulin A; 0 / Paraproteins
  •  go-up   go-down


5. Kyle RA: The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Ann Oncol; 2000;11 Suppl 1:55-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
  • BACKGROUND: Minimal criteria for the diagnosis of multiple myeloma are provided.
  • Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, primary systemic amyloidosis and metastatic carcinoma must be included in the differential diagnosis.
  • Patients with multiple myeloma should not be treated unless they have an increasing M-protein in the serum or urine, development of anemia, hypercalcemia, renal insufficiency, lytic lesions, fractures or extra-medullary plasmacytomas.
  • PATIENTS AND METHODS: This is a review of patients treated with chemotherapy, autologous stem-cell transplantation and allogeneic transplantation.
  • RESULTS: Comparisons of melphalan and prednisone with a variety of combinations of therapeutic agents produces a higher response rate than with melphalan and prednisone but no significant difference in overall survival.
  • Autologous stem-cell transplantation produces a higher response rate and some prolongation of survival but is not curative.
  • CONCLUSIONS: If the patient is younger than 70 years, the physician should consider the possibility of an autologous peripheral blood stem-cell transplant.
  • Autologous stem-cell transplantation does not produce a cure and most patients will relapse.
  • The appropriate timing of an autologous stem-cell transplant has not been ascertained.
  • Another major question is whether double (tandem) transplants are superior to a single autologous stem-cell transplant.
  • A current French Myeloma Group Study randomized study should answer this question.
  • Allogeneic transplantation for multiple myeloma must be made safer because the transplant-related mortality is 40%.
  • The relapse of multiple myeloma following allogeneic transplant is a major problem and consequently the preparative regimens must be improved.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707780.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA62242
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 19
  •  go-up   go-down


6. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA: Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood; 2004 Jul 1;104(1):40-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma.
  • At diagnosis, most patients had monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), with a median creatinine level of 176.8 microM (2.0 mg/dL; range, 79.56-327.08 microM [0.9-3.7 mg/dL]) and evidence of osteomalacia.
  • During the average 65 months (range, 2-238 months) of follow-up, 5 patients developed end-stage renal disease (ESRD) and only 1 of 14 patients with MGUS transformed to multiple myeloma (MM).
  • Chemotherapy offered little benefit on renal functions of MGUS or SMM patients.
  • [MeSH-major] Fanconi Syndrome / pathology. Multiple Myeloma / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15010372.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-62242
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


7. Asai S, Miyachi H, Kobayashi H, Hotta T, Ando Y: Smoldering myeloma associated with zonisamide treatment. Intern Med; 2002 Feb;41(2):138-41
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoldering myeloma associated with zonisamide treatment.
  • Laboratory examination revealed a serum M-protein which consisted of IgG (lambda) and an increased number of plasma cells in the bone marrow, resulting in a diagnosis of smoldering myeloma.
  • Considering his age, zonisamide was suspected to play an etiologic role in the occurrence of smoldering myeloma.
  • [MeSH-major] Agammaglobulinemia / chemically induced. Anticonvulsants / adverse effects. Epilepsy, Generalized / drug therapy. Immunoglobulin lambda-Chains / blood. Isoxazoles / adverse effects. Multiple Myeloma / chemically induced. Myeloma Proteins / analysis
  • [MeSH-minor] Adult. Humans. Intracranial Arteriovenous Malformations / complications. Male. Subarachnoid Hemorrhage / complications. Valproic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. ZONISAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11868602.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Immunoglobulin lambda-Chains; 0 / Isoxazoles; 0 / Myeloma Proteins; 459384H98V / zonisamide; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


8. Nau KC, Lewis WD: Multiple myeloma: diagnosis and treatment. Am Fam Physician; 2008 Oct 1;78(7):853-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma: diagnosis and treatment.
  • Multiple myeloma, the most common bone malignancy, is occurring with increasing frequency in older persons.
  • Skeletal radiographs are important in staging multiple myeloma and revealing lytic lesions, vertebral compression fractures, and osteoporosis.
  • Magnetic resonance imaging and positron emission tomography or computed tomography are emerging as useful tools in the evaluation of patients with myeloma; magnetic resonance imaging is preferred for evaluating acute spinal compression.
  • Nuclear bone scans and dual energy x-ray absorptiometry have no role in the diagnosis and staging of myeloma.
  • The differential diagnosis of monoclonal gammopathies includes monoclonal gammopathy of uncertain significance, smoldering (asymptomatic) and symptomatic multiple myeloma, amyloidosis, B-cell non-Hodgkin lymphoma, Waldenström macroglobulinemia, and rare plasma cell leukemia and heavy chain diseases.
  • Patients with monoclonal gammopathy of uncertain significance or smoldering multiple myeloma should be followed closely, but not treated.
  • Symptomatic multiple myeloma is treated with chemotherapy followed by autologous stem cell transplantation, if possible.
  • It is important that family physicians recognize and appropriately treat multiple myeloma complications.
  • Bone pain is treated with opiates, bisphosphonates, radiotherapy, vertebroplasty, or kyphoplasty; nephrotoxic nonsteroidal anti-inflammatory drugs should be avoided.
  • [MeSH-major] Multiple Myeloma / diagnosis. Multiple Myeloma / therapy
  • [MeSH-minor] Age Factors. Humans. Myeloma Proteins / physiology. Pain / etiology. Plasma Cells / physiology. Risk Factors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841734.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins
  • [Number-of-references] 29
  •  go-up   go-down


9. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE: Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia; 2001 Aug;15(8):1274-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide for previously untreated indolent or smoldering multiple myeloma.
  • We conducted a clinical trial of thalidomide as initial therapy for asymptomatic smoldering (SMM) or indolent multiple myeloma (IMM).
  • Six patients had a confirmed response to therapy with at least 50% or greater reduction in serum and urine monoclonal (M) protein.
  • When minor responses (25-49%) decrease in M protein concentration) were included, 11 of 16 patients (69%) responded to therapy.
  • Pre-treatment MVD was not a significant predictor of response to therapy, median MVD 4 and 12 in responders and non-responders respectively, P = 0.09.
  • We conclude that thalidomide has significant activity in the treatment of newly diagnosed SMM/IMM.
  • However, we do not recommend treatment with thalidomide at this stage since some patients with SMM/IMM can be stable for several months or years without any therapy.
  • Additional randomized trials are needed to determine if thalidomide will delay progression to active multiple myeloma.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Multiple Myeloma / drug therapy. Thalidomide / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11480571.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62242; United States / NCI NIH HHS / CA / CA85818
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


10. Harousseau JL: Optimising patient outcomes in myeloma. Cancer Treat Rev; 2010 May;36 Suppl 2:S33-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimising patient outcomes in myeloma.
  • Multiple myeloma (MM) is an incurable disease, and the goal of therapy is to prolong survival.
  • Newer therapies (thalidomide, lenalidomide, and bortezomib) have contributed to the recent improvements in survival.
  • Optimal integration of these newer therapies into standard practice may be aided by better methods of risk stratification.
  • Supplementation of existing risk stratification methods with new prognostic information, such as cytogenetic data and gene expression profiles, may improve prognostication and help to identify appropriate treatment.
  • The advent of newer therapies has also prompted a reassessment of traditional endpoints and goals of therapy, such as complete response.
  • While complete response correlates with survival in some cases, the correlation is not consistent across all treatment regimens and patient groups, and is therefore not always the most appropriate goal of therapy.
  • With the aim of prolonging survival, trials are currently evaluating newer therapies as long-term maintenance therapy or as prevention therapy for patients with smouldering myeloma.
  • Given that these patients are often asymptomatic and free of clinically active disease, success in this setting depends highly on long-term tolerability of these agents.
  • Treatment of MM should therefore be tailored to the individual patient based on the goals of therapy, patient condition, expected adverse events, and patient preference.
  • [MeSH-major] Multiple Myeloma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Disease Management. Humans. Prognosis. Pyrazines / therapeutic use. Risk Assessment. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20472187.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  • [Number-of-references] 18
  •  go-up   go-down


11. Basić-kes V, Basić-Jukić N, Kes P, Demarin V, Labar B: [Neurologic sequelae of bone changes in multiple myeloma and its therapy]. Acta Med Croatica; 2002;56(3):103-7
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
  • Multiple myeloma (MM) is a plasma cell malignancy characterized by infiltration of bone marrow, bone destruction, infiltration of soft tissues with plasma cells, and suppression of normal hematopoiesis.
  • Full spectrum of plasma cell dyscrasias include monoclonal gammapathy of undetermined significance, smouldering myeloma, indolent multiple myeloma, and fully developed, symptomatic multiple myeloma.
  • Multiple vertebral involvement with the evidence of osteolytic changes in other bones is usual, but solitary vertebral myeloma may occur.
  • Myeloma usually involves the bone of the vertebral body and then spreads into the extradural space.
  • However, patients with solitary extradural myeloma have been reported.
  • Skull myeloma is frequently asymptomatic.
  • Diagnostic approach includes plain X-rays of the skeleton, which was found to be the method of choice for demonstration of osteolytic changes, whereas magnetic resonance with gadolinium enhancement most reliably displays the degree of vertebral involvement and demonstrates any associated soft tissue mass.
  • Current treatment of osteolytic changes in multiple myeloma include chemotherapy, radiotherapy in combination with dexamethasone, monthly infusions of bisphosphonates, surgical decompression, and kyphoplasty.
  • Therapeutic approach is dictated by the presenting symptoms.
  • In case of pain as the predominant symptom, treatment with chemotherapy and radiotherapy may be appropriate.
  • Compressive symptoms are relieved with dexamethasone followed by radiotherapy and chemotherapy.
  • Kyphoplasty is a new method used in the treatment of osteolytic changes of vertebral bodies.
  • Bisphosphonates reduce pain associated with osteolytic changes in multiple myeloma, but also significantly reduce skeletal events (pathologic fracture, spinal cord compression, surgery or irradiation of bone) via unknown mechanism.
  • [MeSH-major] Central Nervous System Diseases / etiology. Multiple Myeloma / diagnosis. Spinal Diseases / diagnosis
  • [MeSH-minor] Humans. Osteolysis / diagnosis. Osteolysis / etiology. Pain / etiology. Pain Management. Spine / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12630341.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 36
  •  go-up   go-down


12. Peest D, Ganser A: [Therapy of multiple myeloma: indications and options]. Internist (Berl); 2007 Dec;48(12):1343-8
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of multiple myeloma: indications and options].
  • [Transliterated title] Therapie des multiplen Myeloms : Indikationen und Möglichkeiten.
  • The multiple myeloma (MM) has an incidence of 3-4/100,000 in the Caucasian population.
  • MM has to be distinguished from smouldering MM and monoclonal gammopathy of uncertain significance (MGUS).
  • In younger patients (<65 years) a good long-term remission is the aim of therapy, while in the elderly patients with comorbidities the aim is a good partial remission with good quality of life.
  • High-dose chemotherapy, often as a tandem transplantation, is part of standard therapy of MM patients <65 years.
  • However, allogeneic stem cell transplantation is the only curative approach.
  • New substances approved for treatment of relapsed MM include bortezomib, thalidomide, and lenalidomide.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Boronic Acids / administration & dosage. Boronic Acids / adverse effects. Bortezomib. Combined Modality Therapy. Diphosphonates / administration & dosage. Diphosphonates / adverse effects. Dose-Response Relationship, Drug. Hematopoietic Stem Cell Transplantation. Humans. Melphalan / administration & dosage. Melphalan / adverse effects. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Pyrazines / administration & dosage. Pyrazines / adverse effects. Remission Induction. Thalidomide / administration & dosage. Thalidomide / adverse effects. Thalidomide / analogs & derivatives. Tumor Burden

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007;120 Suppl 12:40-61 [17405120.001]
  • [Cites] Lancet. 1992 Oct 31;340(8827):1049-52 [1357451.001]
  • [Cites] Br J Haematol. 1998 Feb;100(2):317-25 [9488619.001]
  • [Cites] Lancet. 1983 Oct 8;2(8354):822-4 [6137651.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Blood. 2001 Jul 15;98(2):492-4 [11435324.001]
  • [Cites] Bone Marrow Transplant. 2003 Dec;32(12):1145-51 [14647268.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3052-7 [15265788.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1196-8 [8562947.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):183-96 [17241924.001]
  • [Cites] JAMA. 1969 Jun 2;208(9):1680-5 [5818682.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):991-5 [11521808.001]
  • [Cites] N Engl J Med. 2007 Mar 15;356(11):1110-20 [17360989.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3919-24 [12393448.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):1-18 [16258534.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3832-42 [9850028.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):377-87 [11693896.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Hematol J. 2003;4(6):379-98 [14671610.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • (PMID = 17960351.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Diphosphonates; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  • [Number-of-references] 26
  •  go-up   go-down


13. Martín A, García-Sanz R, Hernández J, Bladé J, Suquía B, Fernández-Calvo J, González M, Mateo G, Orfao A, San Miguel JF: Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol; 2002 Jul;118(1):239-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
  • Twelve patients with smouldering or indolent multiple myeloma (MM) received 12 courses of intravenous pamidronate as a single agent to evaluate both the antitumour and bone metabolism effects.
  • One patient achieved minor response, eight had stable disease, and three - all indolent MM - showed disease progression.
  • Markers for bone resorption and bone formation decreased with treatment.
  • These results suggest that pamidronate treatment reduces bone turnover in smouldering or indolent MM, but has no significant antitumour effect.
  • [MeSH-major] Bone Remodeling / drug effects. Diphosphonates / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Aged. Disease Progression. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Failure

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100153.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


14. Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G: Thalidomide in the management of multiple myeloma. Semin Hematol; 2001 Jul;38(3):250-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide in the management of multiple myeloma.
  • Thalidomide has recently been shown to have significant activity in refractory multiple myeloma (MM).
  • The addition of thalidomide to dexamethasone and chemotherapy for the management of post-transplant relapses results in higher response rates.
  • The early results of the Total Therapy II trial for newly diagnosed MM patients show an unprecedented complete remission (CR) and near-CR rate of 69% after two melphalan-based transplants (whether or not receiving thalidomide).
  • In addition, available clinical trial information involving at least 20 patients confirms that thalidomide is active in one third of patients in single-agent trials for refractory disease, with response rates increasing to 50% to 60% in combination with dexamethasone and to as high as 80% in combination with dexamethasone and chemotherapy.
  • When applied as primary therapy in smoldering myeloma, one third of patients experienced 50% paraprotein reduction (PPR); in combination with dexamethasone pulsing, 70% to 80% of symptomatic patients responded.
  • Thus, thalidomide is a major new tool in the treatment armamentarium of MM.
  • The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Multiple Myeloma / drug therapy. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11486313.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA55819
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 48
  •  go-up   go-down


15. Rosiñol L, Bladé J, Esteve J, Aymerich M, Rozman M, Montoto S, Giné E, Nadal E, Filella X, Queralt R, Carrió A, Montserrat E: Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol; 2003 Nov;123(4):631-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoldering multiple myeloma: natural history and recognition of an evolving type.
  • Patients with smoldering multiple myeloma (SMM) meet the diagnostic criteria of multiple myeloma (MM) but are asymptomatic.
  • The median serum M-protein and proportion of bone marrow plasma cells were 36 g/l and 27% respectively.
  • Two subsets of SMM were identified: (i) evolving SMM (n = 22), characterized by a progressive increase in serum M-protein, a previously recognized monoclonal gammopathy of undetermined significance (MGUS) and a significant higher proportion of IgA type and (ii) non-evolving SMM (n = 26) with stable M-protein that abruptly increases when symptomatic MM develops.
  • Thirty-four patients developed symptomatic MM.
  • The median time to progression in the overall series was 3.2 years and the only feature associated with a shorter time to progression was the evolving versus non-evolving type (1.3 vs. 3.9 years respectively, P = 0.007).
  • Fifty-seven per cent of patients that required chemotherapy showed no or minimal response.
  • The median survival from diagnosis and from progression was 8.2 and 3.5 years respectively.
  • [MeSH-major] Multiple Myeloma / diagnosis. Myeloma Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Disease Progression. Female. Humans. Male. Middle Aged. Plasma Cells / pathology. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616966.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins
  •  go-up   go-down


16. Gozzetti A, Gennari L, Merlotti D, Salvadori S, De Paola V, Avanzati A, Franci B, Marchini E, Tozzi M, Campagna MS, Nuti R, Lauria F, Martini G: The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif Tissue Int; 2008 Apr;82(4):258-62
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of zoledronic acid on serum lipids in multiple myeloma patients.
  • The mechanism of action of these drugs has not been completely clarified, but it has been observed that N-BPs may inhibit squalene synthase or farnesyl pyrophosphate synthase.
  • To explore the effects of ZA on serum lipids, we studied 26 patients with smoldering myeloma at diagnosis.
  • In all subjects, total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and C-terminal telopeptide of type I collagen (CTX) were measured at baseline and after 1, 3, and 6 months.
  • In conclusion, ZA given intravenously at high doses in patients with smoldering myeloma seems to be able to modify the lipid profile with an improvement of atherosclerotic risk index.
  • [MeSH-major] Diphosphonates / pharmacology. Imidazoles / pharmacology. Multiple Myeloma / blood. Multiple Myeloma / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Atherosclerosis / metabolism. Bone Density Conservation Agents / therapeutic use. Cholesterol, HDL / metabolism. Collagen / chemistry. Female. Humans. Lipids / chemistry. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418538.001).
  • [ISSN] 0171-967X
  • [Journal-full-title] Calcified tissue international
  • [ISO-abbreviation] Calcif. Tissue Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Cholesterol, HDL; 0 / Diphosphonates; 0 / Imidazoles; 0 / Lipids; 6XC1PAD3KF / zoledronic acid; 9007-34-5 / Collagen
  •  go-up   go-down


17. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol; 2003 Jan 1;21(1):16-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
  • PURPOSE: To evaluate the activity of thalidomide in patients with asymptomatic multiple myeloma and of thalidomide-dexamethasone in patients with previously untreated symptomatic myeloma.
  • PATIENTS AND METHODS: Twenty-eight patients with previously untreated asymptomatic myeloma were treated with thalidomide 100 to 200 mg orally (PO) at bedtime (qhs) with serial increments of 50 to 100 mg at weekly intervals, as tolerated to a maximum of 600 mg PO qhs.
  • Forty consecutive previously untreated patients with symptomatic myeloma were also treated as above (maximum dose 400 mg) and received dexamethasone 20 mg/m(2) for 4 days beginning on days 1, 9, and 17; the second and third cycles of repeated dexamethasone were begun on day 30.
  • The median time to remission was 4.2 months with thalidomide alone and 0.7 months with thalidomide-dexamethasone.
  • Five deaths have occurred as a result of multiple myeloma (two patients), infection (one patient), unknown cause (one patient), and a possible thromboembolic event (one patient).
  • CONCLUSION: Thalidomide alone was effective in patients with newly diagnosed myeloma.
  • These observations support further studies of this promising combination for patients with newly diagnosed multiple myeloma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Dexamethasone / administration & dosage. Humans. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506164.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


18. Armellini A, Sarasquete ME, García-Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfão A, Gutiérrez NC, González M, San Miguel JF: Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol; 2008 Apr;141(2):212-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
  • RAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines.
  • ZHX2 was weakly expressed in high-risk/proliferative disease compared to low-risk or indolent disease.
  • High ZHX2 expression was associated with better response and longer survival after high-dose therapy.
  • RCBTB2 expression was weaker in hyperdiploid versus non-hyperdiploid cases while RAN was more expressed in symptomatic MM and cell lines.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Homeodomain Proteins / metabolism. Multiple Myeloma / metabolism. Neoplasm Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / metabolism. Female. Gene Expression. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / metabolism. Plasma Cells / metabolism. Prognosis. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. ran GTP-Binding Protein / genetics. ran GTP-Binding Protein / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353163.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 0 / RAN protein, human; 0 / RCBTB2 protein, human; 0 / Transcription Factors; 0 / ZHX2 protein, human; EC 3.6.5.2 / ran GTP-Binding Protein
  •  go-up   go-down


19. Tricot GJ: New insights into role of microenvironment in multiple myeloma. Int J Hematol; 2002 Aug;76 Suppl 1:334-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights into role of microenvironment in multiple myeloma.
  • Multiple Myeloma (MM) is a malignant disease of terminally differentiated B cells.
  • It most likely originates in a B cell which has traversed the germinal center and has been exposed there extensively to antigens based on the high number of somatic mutations in the complementarity determining regions.
  • The cell of origin is either a plasmablast, or more likely, a memory B-cell.
  • Typically MM goes through different phases from indolent (MGUS, smoldering myeloma) to overt myeloma and then to a fulminant phase, characterized by extramedullary manifestations, high LDH, immature morphology and increased proliferation rate.
  • In the indolent phase, the disease already has acquired major cytogenetic abnormalities as demonstrated by FISH and DNA flow cytometry.
  • It has a gene pattern very similar to myeloma cells on gene array analysis.
  • In the early stages of overt MM, the myeloma cells are completely dependent upon the micro-environment for their growth and survival.
  • The interaction between myeloma cells and micro-environment causes bone disease, genetic instability and more importantly, drug-resistance, which is caused by upregulation of anti-apoptotic factors, resistance to apoptosis induced by FAS and TRAIL activation, and by cell adhesion-induced growth arrest.
  • In this phase of the disease, MM is susceptible to chemotherapy, if delivered with adequate intensity.
  • In the fulminant phase of MM, myeloma cells have acquired sufficient genetic alternations to become completely independent of the micro-environment which allows them to grow at extramedullary sites.
  • Because of the many DNA breaks necessary for immature B cells to become mature plasma cells, B cells already have inherent genetic instability.
  • DNA breaks are necessary for VDJ recombinations, somatic mutations and isotype switching and it is therefore not surprising that genetic alternations frequently occur at the Ig heavy chain site at 14q32, which is abnormal in three quarters of myeloma patients.
  • The issues of bone disease, drug resistance and cytogenetics will be addressed in detail during this presentation.
  • [MeSH-major] Cell Communication / physiology. Multiple Myeloma / pathology
  • [MeSH-minor] Drug Resistance, Neoplasm. Humans. Osteoclasts / cytology. Osteoclasts / secretion. Stromal Cells / cytology. Stromal Cells / secretion

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]
  • [Cites] Cell. 1997 Apr 18;89(2):309-19 [9108485.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1805-12 [8781438.001]
  • [Cites] Exp Hematol. 1999 Aug;27(8):1229-41 [10428500.001]
  • [Cites] Br J Haematol. 1999 May;105(2):441-4 [10233418.001]
  • [Cites] Cell. 1998 Apr 17;93(2):165-76 [9568710.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4015-23 [9199336.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1903-10 [7655019.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1658-67 [10029595.001]
  • [Cites] J Immunol. 1998 Jan 1;160(1):395-402 [9551996.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1104-12 [8562936.001]
  • [Cites] Oncogene. 1996 Oct 3;13(7):1489-97 [8875987.001]
  • [Cites] Blood. 1998 Jan 1;91(1):3-21 [9414264.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] Leukemia. 1998 Feb;12(2):220-9 [9519785.001]
  • [Cites] Nat Med. 1999 Apr;5(4):412-7 [10202930.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1878-89 [10477716.001]
  • (PMID = 12430876.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


20. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S: Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol; 2010 Oct;85(10):737-40
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
  • We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM).
  • Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent MM without the need for immediate therapy.
  • Disease progression was defined using modified American Society of Hematology/Food and Drug Administration consensus panel criteria for SMM.
  • Thirty-one patients were enrolled; 29 (19 SMM and 10 indolent MM) were eligible.
  • The median time to progression (TTP) to symptomatic myeloma was 35 months.
  • Median overall survival from diagnosis was 86 months; median survival from onset of symptomatic myeloma was 49 months.
  • Randomized trials are needed to determine the role of early therapy in SMM.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):690-7 [20026810.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2210-6 [12114422.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):16-9 [12506164.001]
  • [Cites] Leukemia. 2003 Apr;17(4):775-9 [12682636.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Clin Ther. 1999 Feb;21(2):319-30 [10211535.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] N Engl J Med. 2007 Jun 21;356(25):2582-90 [17582068.001]
  • [Cites] Leukemia. 2008 Feb;22(2):231-9 [17972944.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3122-5 [18669874.001]
  • [Cites] Leukemia. 2009 Jan;23(1):3-9 [18971951.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1274-6 [11480571.001]
  • (PMID = 20730790.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / R01 CA107476; United States / NCI NIH HHS / CA / CA107476; United States / NCI NIH HHS / CA / CA62242
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide
  • [Other-IDs] NLM/ NIHMS228591; NLM/ PMC3022372
  •  go-up   go-down


21. Zeldis JB, Knight RD, Jacques C, Tozer A, Bizzari JP: Lenalidomide in multiple myeloma: current role and future directions. Expert Opin Pharmacother; 2010 Apr;11(5):829-42
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide in multiple myeloma: current role and future directions.
  • IMPORTANCE OF THE FIELD: Lenalidomide and other new agents are improving survival of multiple myeloma patients.
  • This review describes current data on lenalidomide in myeloma and how the unique properties of lenalidomide may lend its use in new settings, such as maintenance and preventive therapy.
  • AREAS COVERED IN THIS REVIEW: This review covers the activity of lenalidomide in multiple myeloma, efficacy in both newly diagnosed and relapsed/refractory patients, how to manage effectively common adverse events observed with lenalidomide, and its potential use in new settings based on clinical trials published up to 2009.
  • WHAT THE READER WILL GAIN: This review describes the mechanism of action of lenalidomide in myeloma which provides the basis for its clinical use in newly diagnosed, relapsed/refractory, and high-risk smoldering myeloma in combination with other agents.
  • Strategies to reduce or effectively manage myelosuppression and thromboembolic events, the main adverse events associated with lenalidomide plus dexamethasone therapy, are also described.
  • TAKE HOME MESSAGE: Lenalidomide is an oral immunomodulatory drug that is highly effective in treating multiple myeloma, has a favorable safety profile and is now being evaluated as maintenance therapy, preventive therapy and in combination with other new agents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Dexamethasone / administration & dosage. Humans. Neoplasm Recurrence, Local. Survival Rate. Thalidomide / administration & dosage. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Expert Opin Pharmacother. 2010 Sep;11(13):2273
  • [ErratumIn] Expert Opin Pharmacother. 2011 Mar;12(4):679
  • (PMID = 20210686.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  • [Number-of-references] 87
  •  go-up   go-down


22. Yakushijin Y, Sakai I, Takada K, Yasukawa M, Fujita S: [Double B-cell malignancies with simultaneous onset]. Rinsho Ketsueki; 2004 Mar;45(3):218-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double B-cell malignancies with simultaneous onset].
  • We encountered a case of a 59-year-old female who simultaneously contracted a non-Hodgkin lymphoma (NHL) and a plasma cell neoplasm.
  • She was diagnosed as having NHL (follicular center lymphoma, grade I, stage IIA) after an open tumor biopsy, and treated by cycles of CHOP chemotherapy which resulted in complete remission.
  • A tumor biopsy was performed laparoscopically at that time.
  • When a bone marrow puncture was performed because of a condition of monoclonal gammopathy which had continued for two years, a smoldering myeloma was additionally diagnosed.
  • This diagnosis was made after the presence of IgG-lambda M protein when the marrow showed an increase in the number of plasma cells.
  • In a Southern blot analysis which studied the abdominal tumor and the bone marrow cells, each B-cell tumor had a different IgH gene rearrangement pattern.
  • Therefore, this case was diagnosed as an example of the simultaneous existence of two different B-cell tumors.
  • [MeSH-major] Abdominal Neoplasms. Lymphoma, Follicular. Multiple Myeloma. Neoplasms, Multiple Primary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. B-Lymphocytes / pathology. Fatal Outcome. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15103935.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


23. Kyle RA: Multiple Myeloma. Diagnostic challenges and standard therapy. Semin Hematol; 2001 Apr;38(2 Suppl 3):11-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple Myeloma. Diagnostic challenges and standard therapy.
  • In the diagnosis of multiple myeloma (MM), the clinician must exclude other disorders in which a plasma cell reaction may occur such as rheumatoid arthritis and connective tissue disorders, or metastatic carcinoma where the patient may have osteolytic lesions associated with bone metastases.
  • Patients with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS) have none of the complicating features of MM and do not require treatment with potentially toxic agents.
  • The plasma cell labeling index can help make a differential diagnosis of MM from SMM.
  • In addition, SMM or MGUS patients have few or no circulating plasma cells.
  • High-dose chemotherapy and stem cell support prolong overall survival in contrast to conventional therapy.
  • If stem cell transplantation is considered, it is important to harvest the cells before using alkylating agents to obtain a sufficient number of cells.
  • Supportive treatment consists of the occasional use of erythropoietin to maintain adequate hemoglobin levels and adequate hydration to protect renal function.
  • Vaccination against pneumococcal infections and the prophylactic use of antibiotic therapy during the first 2 months of treatment can be beneficial.
  • Recognizing the symptoms of spinal cord compression and initiating dexamethasone therapy promptly to prevent paraplegia are critical.
  • [MeSH-major] Multiple Myeloma / diagnosis. Multiple Myeloma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Hematopoietic Stem Cell Transplantation. Humans

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11309703.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 14
  •  go-up   go-down


24. Gabay C, Lamacchia C, Palmer G: IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol; 2010 Apr;6(4):232-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of IL-1 are tightly controlled by several naturally occurring inhibitors, such as IL-1 receptor antagonist (IL-1Ra), IL-1 receptor type II (IL-1RII), and other soluble receptors.
  • Numerous IL-1 inhibitors have been developed and tested primarily in rheumatoid arthritis, with only modest effects.
  • Successful treatment with IL-1 blockers has also been reported in other hereditary autoinflammatory diseases, as well as in nonhereditary inflammatory diseases, such as Schnizler syndrome, systemic-onset juvenile idiopathic arthritis and adult Still disease.
  • Finally, preliminary results indicating that IL-1 targeting is efficacious in type 2 diabetes and smoldering myeloma have further broadened the spectrum of IL-1-driven diseases.
  • [MeSH-major] Interleukin-1 / antagonists & inhibitors. Interleukin-1 / metabolism. Rheumatic Diseases / blood. Rheumatic Diseases / drug therapy
  • [MeSH-minor] Animals. Cohort Studies. Disease Models, Animal. Drug Delivery Systems. Female. Humans. Inflammation / blood. Inflammation / physiopathology. Inflammation Mediators / blood. Interleukin 1 Receptor Antagonist Protein / therapeutic use. Interleukin-1beta / drug effects. Interleukin-1beta / metabolism. Male. Mice. Prognosis. Receptors, Interleukin / antagonists & inhibitors. Receptors, Interleukin / drug effects. Risk Assessment. Signal Transduction. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20177398.001).
  • [ISSN] 1759-4804
  • [Journal-full-title] Nature reviews. Rheumatology
  • [ISO-abbreviation] Nat Rev Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-1; 0 / Interleukin-1beta; 0 / Receptors, Interleukin
  • [Number-of-references] 119
  •  go-up   go-down


25. Sanders J, Crawford B, Gibson J, Joy Ho P, Iland H, Joshua D: Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). Int J Lab Hematol; 2007 Oct;29(5):395-7
MedlinePlus Health Information. consumer health - Osteoporosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Multiple Myeloma / complications. Osteoporosis / drug therapy. Paraproteinemias / complications

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824924.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


26. Kyle RA: New strategies for MGUS and smoldering multiple myeloma. Clin Adv Hematol Oncol; 2004 Aug;2(8):507, 509
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New strategies for MGUS and smoldering multiple myeloma.
  • [MeSH-major] Multiple Myeloma / prevention & control. Paraproteinemias / drug therapy
  • [MeSH-minor] Diphosphonates / therapeutic use. Disease Management. Disease Progression. Drug Design. Humans. Immunoglobulin kappa-Chains / blood. Immunoglobulin lambda-Chains / blood. Myeloma Proteins / analysis. Paraproteins / analysis. Prognosis. Randomized Controlled Trials as Topic. Risk Factors. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16163229.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Myeloma Proteins; 0 / Paraproteins; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


27. Sorli ML, Gimeno E, Abella E, Besses C, Knobel H: Smoldering myeloma in HIV patient: a complete remission after antiretroviral therapy. Leuk Res; 2008 Sep;32(9):1482-3
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoldering myeloma in HIV patient: a complete remission after antiretroviral therapy.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Multiple Myeloma / drug therapy


28. Cortesão E, Espadana A, Laranjeiro P, Jara M, Orfão A: Successful treatment with VAD of a myelodysplastic syndrome occurring during the course of a smoldering multiple myeloma. Leuk Res; 2009 Jan;33(1):195-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with VAD of a myelodysplastic syndrome occurring during the course of a smoldering multiple myeloma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Aged. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Treatment Outcome. Vincristine / administration & dosage






Advertisement